cc-223
Small moleculeexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 20, 2010 (NCT01177397)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Glioblastoma · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
Mechanism of action
- Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
ATP-competitive mTORC1/mTORC2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545151 ↗
Also known as
- cc-223
- cc-223
- cc-223
- cc-223
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04998760 | Phase 2 | Aug 3, 2021 | Chongqing Medical University |
| NCT04337463 | N/A | Apr 30, 2020 | Sichuan University |
| NCT03591965 | Phase 2 | Aug 7, 2018 | Antengene Corporation |
| NCT02031419 | Phase 1 | Dec 18, 2013 | Celgene |
| NCT01896323 | Phase 1 | Jul 1, 2013 | Celgene |
| NCT01611467 | Phase 1 | Jun 1, 2012 | Celgene |
| NCT01545947 | Phase 1 | May 1, 2012 | Celgene |
| NCT01177397 | Phase 1/Phase 2 (Phase 2) | Jul 20, 2010 | Celgene |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 5 | 5 | 2 | 2010 |
| Antengene Corporation | For profit | 1 | 1 | 1 | 2018 |
| Chongqing Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1